Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

03.29.16

EyeGate Reports Full-year 2015 Financial Results and Provides Business Update

WALTHAM, Mass., March 29, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery...
Read more
03.07.16

EyeGate Pharma Acquires Jade Therapeutics

Transaction enhances development pipeline with addition of new ophthalmic platform technology  First Jade product to enter clinic later this year WALTHAM, Mass., March 07, 2016 -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG)...
Read more
01.19.16

EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis

Data Anticipated Q1 2017 WALTHAM, Mass., Jan. 19, 2016 -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and...
Read more
01.14.16

Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 12th Annual Investor Conference

WALTHAM, Mass., January 14, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG, EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery...
Read more
11.12.15

EyeGate Reports Third Quarter 2015 Financial Results and Provides Business Update

WALTHAM, Mass., November 12, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems...
Read more
11.05.15

EyeGate Announces Interim Data from Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema Patients

WALTHAM, Mass., November 5, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems...
Read more
10.15.15

EyeGate Pharma Receives USPTO Notice of Allowance for Next Generation of Proprietary Iontophoretic Delivery System

Patent to Provide Broad Coverage for EyeGate II® Delivery System with Pre-filled Drug Applicator Also, Patent Covering Proprietary Dexamethasone Phosphate Pharmaceutical Formulation Granted WALTHAM, Mass., Oct. 15, 2015 -- Eyegate...
Read more
09.08.15

The Wall Street Transcript Interview with EyeGate CEO, Stephen From

Click here for the complete article.
Read more